Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 4
2006 1
2007 5
2008 4
2009 1
2010 3
2011 5
2012 3
2013 2
2014 3
2015 12
2016 9
2017 10
2018 9
2019 14
2020 20
2021 16
2022 10
2023 12
2024 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Sporozoite immunization: innovative translational science to support the fight against malaria.
Richie TL, Church LWP, Murshedkar T, Billingsley PF, James ER, Chen MC, Abebe Y, Natasha Kc, Chakravarty S, Dolberg D, Healy SA, Diawara H, Sissoko MS, Sagara I, Cook DM, Epstein JE, Mordmüller B, Kapulu M, Kreidenweiss A, Franke-Fayard B, Agnandji ST, López Mikue MA, McCall MBB, Steinhardt L, Oneko M, Olotu A, Vaughan AM, Kublin JG, Murphy SC, Jongo S, Tanner M, Sirima SB, Laurens MB, Daubenberger C, Silva JC, Lyke KE, Janse CJ, Roestenberg M, Sauerwein RW, Abdulla S, Dicko A, Kappe SHI, Sim BKL, Duffy PE, Kremsner PG, Hoffman SL. Richie TL, et al. Among authors: agnandji st. Expert Rev Vaccines. 2023 Jan-Dec;22(1):964-1007. doi: 10.1080/14760584.2023.2245890. Epub 2023 Aug 11. Expert Rev Vaccines. 2023. PMID: 37571809 Free PMC article. Review.
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.
Vianello E, Persson J, Andersson B, van Veen S, Dias TL, Santoro F, Östensson M, Obudulu O, Agbajogu C, Torkzadeh S; VSV-EBOVAC; VSV-EBOPLUS Consortia; Nakaya HI, Medaglini D, Siegrist CA, Ottenhoff THM, Harandi AM. Vianello E, et al. iScience. 2023 Nov 23;26(12):108574. doi: 10.1016/j.isci.2023.108574. eCollection 2023 Dec 15. iScience. 2023. PMID: 38162033 Free PMC article.
Ebola vaccine R&D: Filling the knowledge gaps.
Medaglini D, Harandi AM, Ottenhoff TH, Siegrist CA; VSV-Ebovac Consortium. Medaglini D, et al. Sci Transl Med. 2015 Dec 9;7(317):317ps24. doi: 10.1126/scitranslmed.aad3106. Sci Transl Med. 2015. PMID: 26659569 Free PMC article. Review.
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Huttner A, Agnandji ST, Engler O, Hooper JW, Kwilas S, Ricks K, Clements TL, Jonsdottir HR, Nakka SS, Rothenberger S, Kremsner P, Züst R, Medaglini D, Ottenhoff T, Harandi AM, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Among authors: agnandji st. Clin Microbiol Infect. 2023 Dec;29(12):1587-1594. doi: 10.1016/j.cmi.2023.08.026. Epub 2023 Sep 3. Clin Microbiol Infect. 2023. PMID: 37661067
Single dose treatment of malaria - current status and perspectives.
Mischlinger J, Agnandji ST, Ramharter M. Mischlinger J, et al. Among authors: agnandji st. Expert Rev Anti Infect Ther. 2016 Jul;14(7):669-78. doi: 10.1080/14787210.2016.1192462. Epub 2016 Jun 7. Expert Rev Anti Infect Ther. 2016. PMID: 27254098 Review.
Monoclonal antibodies for the treatment of Ebola virus disease.
Moekotte AL, Huson MA, van der Ende AJ, Agnandji ST, Huizenga E, Goorhuis A, Grobusch MP. Moekotte AL, et al. Among authors: agnandji st. Expert Opin Investig Drugs. 2016 Nov;25(11):1325-1335. doi: 10.1080/13543784.2016.1240785. Epub 2016 Oct 8. Expert Opin Investig Drugs. 2016. PMID: 27676206 Review.
Ebola vaccines for mass immunisation in affected regions.
Agnandji ST, Loembe MM. Agnandji ST, et al. Lancet Infect Dis. 2022 Jan;22(1):8-10. doi: 10.1016/S1473-3099(21)00226-7. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529960 No abstract available.
Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria.
Bell GJ, Gyaase S, Goel V, Adu B, Mensah B, Essone P, Dosoo D, Osei M, Niare K, Wiru K, Brandt K, Emch M, Ghansah A, Asante KP, Mvalo T, Agnandji ST, Juliano JJ, Bailey JA. Bell GJ, et al. Among authors: agnandji st. BMC Infect Dis. 2023 Oct 23;23(1):716. doi: 10.1186/s12879-023-08699-7. BMC Infect Dis. 2023. PMID: 37872492 Free PMC article.
Bacterial versus non-bacterial infections: a methodology to support use-case-driven product development of diagnostics.
Escadafal C, Geis S, Siqueira AM, Agnandji ST, Shimelis T, Tadesse BT, Massinga Loembé M, Harris V, Fernandez-Carballo BL, Macé A, Ongarello S, Rodriguez W, Dittrich S. Escadafal C, et al. Among authors: agnandji st. BMJ Glob Health. 2020 Oct;5(10):e003141. doi: 10.1136/bmjgh-2020-003141. BMJ Glob Health. 2020. PMID: 33087393 Free PMC article. Review.
147 results